Clinical Trials
51
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (51 trials with phase data)• Click on a phase to view related trials
Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC
- Conditions
- Metastatic Non-small Cell Lung CancerNSCLC
- Interventions
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 61
- Registration Number
- NCT03164772
- Locations
- 🇺🇸
Research Facility, Milwaukee, Wisconsin, United States
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
- Conditions
- Ovarian CancerAppendiceal CancerColorectal Cancer
- Interventions
- First Posted Date
- 2016-11-15
- Last Posted Date
- 2022-12-22
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 67
- Registration Number
- NCT02963831
- Locations
- 🇺🇸
Research Facility, Charlottesville, Virginia, United States
Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer
- Conditions
- Non-small Cell Lung CancerCarcinomaNSCLC
- Interventions
- First Posted Date
- 2016-09-13
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 2
- Registration Number
- NCT02898116
- Locations
- 🇺🇸
Research Facility, New York, New York, United States
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
- Conditions
- Esophageal Cancer
- Interventions
- First Posted Date
- 2016-04-12
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 73
- Registration Number
- NCT02735239
- Locations
- 🇬🇧
Research Facility, Southampton, United Kingdom
Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2016-03-23
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 6
- Registration Number
- NCT02716805
- Locations
- 🇺🇸
Research Facility, New York, New York, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 11
- Next
News
CAR-T Cell Therapy with On/Off Switch Shows Promise in Preclinical Studies
Researchers have developed a novel CAR-T cell therapy that can be controlled with existing oral drugs, offering an on/off switch for enhanced safety and efficacy.
AI-Powered NeoDisc Pipeline Accelerates Personalized Cancer Vaccine Development
Researchers have developed NeoDisc, an AI-enabled computational pipeline integrating multi-omics data for personalized cancer vaccine development.